Mylan (MYL) Suit Against FDA Over Hear Drug Dismissed - Bloomberg
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan, Inc. (NASDAQ: MYL) saw a little volume move higher following headlines that its suit against the FDA over a generic heart drug was dismissed, according to Bloomberg headlines.
Shares are down 1.4 percent on the session, but off of lows.
Shares are down 1.4 percent on the session, but off of lows.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioAge Labs begins Phase 2 trial of NLRP3 inhibitor BGE-102
- Ernexa targets Q4 2026 for first-in-human ovarian cancer trial
- AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
Create E-mail Alert Related Categories
FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
